Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT06995898 · View on ClinicalTrials.gov ↗
Study Summary
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
- DEVICE Device Usage
- PROCEDURE Multi-Cancer Detection Test
Study Locations (20)
Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown
- Henry Ford Health Center - Brownstown — Brownstown
- Henry Ford Health Center - Chesterfield — Chesterfield
- Henry Ford Macomb Hospital-Clinton Township — Clinton Township
- Henry Ford Medical Center-Fairlane — Dearborn
- Henry Ford Hospital — Detroit
- Henry Ford Medical Center - Detroit Northwest — Detroit
- Henry Ford Medical Center-Cottage — Grosse Pointe Farms
- Henry Ford Medical Center - Livonia — Livonia
- Henry Ford Medical Center-Columbus — Novi
Colorado
- Keefe Memorial Hospital — Cheyenne Wells
- Kaiser Permanente-Franklin — Denver
- Poudre Valley Hospital — Fort Collins
- Cancer Care and Hematology-Fort Collins — Fort Collins
- UCHealth Greeley Hospital — Greeley
- Kaiser Permanente-Rock Creek — Lafayette
- Kaiser Permanente-Lone Tree — Lone Tree
- Medical Center of the Rockies — Loveland
California
- Kaiser Permanente-Division of Research — Pleasanton
Hawaii
- Kaiser Permanente Moanalua Medical Center — Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24,000 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2029-06-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06995898
The ClinicalTrials.gov registry entry for NCT06995898 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 24,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 2,390 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions — of which Biospecimen Collection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06995898 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Michigan, Colorado, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06995898 about?
NCT06995898 is a clinical study titled "The Vanguard Study: Testing a New Way to Screen for Cancer". The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand ho...
What is the current status of trial NCT06995898?
This trial is currently recruiting. It is a NA study. The enrollment target is 24,000 participants. The study started on 2025-06-16. Estimated completion is 2029-06-30.
What conditions does trial NCT06995898 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Ovarian Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06995898?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER), Device Usage (DEVICE), Multi-Cancer Detection Test (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06995898?
This trial is sponsored by National Cancer Institute (NCI), which has 2,390 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06995898 being conducted?
This trial has 20 study locations across California, Colorado, Hawaii, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.